Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05519384
Other study ID # ISCRNK01001
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date September 14, 2022
Est. completion date December 2025

Study information

Verified date August 2022
Source Institute of Hematology & Blood Diseases Hospital
Contact Min Ruan, MD
Phone +8613602177144
Email ruanmin@ihcams.ac.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, single-center, single-arm exploratory clinical study, aiming to complete the preliminary clinical observation of 12 children with relapsed/refractory acute myeloid leukemia treated with JK500 cell injection to evaluate the safety of clinical infusion and the initial efficacy of JK500 cell injection in the treatment of children with relapsed/refractory acute myeloid leukemia.


Description:

The Main components of JK500 cell injection are regenerative natural killer (NK) cells derived from human embryonic stem cells and 0.9% sodium chloride solution.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date December 2025
Est. primary completion date November 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: 1. Age =18, male or female; 2. Patients diagnosed as acute myeloid leukemia (AML) according to the revised World Health Organization (WHO) criteria in 2016; 3. Patients who failed to achieve CR after two standard-dose induction therapy or had recurrence within six months after CR; 4. The subject or the guardian of the subject must fully understand the purpose, nature, method and possible adverse reactions of the test, agree the subject as the subject, and sign the informed consent. Exclusion Criteria: 1. Acute promyelocytic leukemia, chronic myelocytic leukemia, acute mixed-cell leukemia or known central nervous system leukemia; 2. AML associated with congenital syndromes such as Down syndrome, Fanconi's anemia, Bloom's syndrome, Koch's syndrome, or congenital aplastic anemia; 3. The subjects have active virus infection, and during the screening period, the serum virology test is performed, and the human immunodeficiency virus (HIV) antibody is positive, hepatitis B surface antigen or E antigen is positive, hepatitis C antibody is positive, or treponema pallidum antibody is positive; 4. Presence of active systemic infection; Participated in a drug trial within the past 4 weeks; 5. Patients who suffered from a clinically significant disease within 28 days before receiving the study product or underwent a major surgical operation within 28 days before receiving the study product, or are expected to need major surgery during the trial; 6. children with liver and kidney dysfunction, including: 1. Serum creatinine >2× upper limit of normal reference value; 2. Serum total bilirubin > 2× upper limit of normal reference value; 3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2× upper limit of normal reference values 7. Children who have used live attenuated vaccine 4 weeks before administration or plan to use live attenuated vaccine within 6 months after administration; 8. Have any other conditions that may cause the subject to be unable to complete the study or present a significant risk to the subject in the opinion of the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
JK500 cell injection,cyclophosphamide,Fludarabine
After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/?/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.

Locations

Country Name City State
China Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences Tianjin Tianjin

Sponsors (3)

Lead Sponsor Collaborator
Institute of Hematology & Blood Diseases Hospital Bejing Institute for Stem Cell and Regenerative Medicine, Institute for Stem cell and Regeneration, Chinese Academy of Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity (DLT) DLT evaluation is defined as adverse events or laboratory abnormalities that occur within 4 weeks after investigational drug administration, are unrelated to external causes such as progressive disease, concomitant disease, and concomitant medications, including hematologic and non-hematologic adverse events (grade according to NCI CTCAE 5.0). 28 days
Secondary Objective Response Rate (ORR) ORR was defined as complete response (CR)+ incomplete bone marrow recovery (CRi) + partial response (PR). Treatment response will be assessed periodically until the end of treatment and up to 24 months after the first injection. 24 months
Secondary Minimal Residual Disease (MRD) To observe the MRD status in bone marrow. 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05043571 - CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia Phase 1
Active, not recruiting NCT04874480 - Tegavivint for the Treatment of Relapsed or Refractory Leukemia Phase 1
Completed NCT04597086 - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients N/A
Recruiting NCT05495035 - Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL Phase 1
Withdrawn NCT05321940 - Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias Phase 1
Recruiting NCT04722952 - PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML Phase 3
Recruiting NCT04684472 - Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies Phase 1
Recruiting NCT04470947 - Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies
Recruiting NCT04282811 - Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
Recruiting NCT05046444 - Solving Riddles Through Sequencing
Recruiting NCT05576532 - Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia Phase 2
Recruiting NCT05164042 - Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Completed NCT02512926 - Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Phase 1
Recruiting NCT05870995 - Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia Phase 2
Recruiting NCT03799224 - Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Phase 2/Phase 3
Recruiting NCT06006403 - Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm Phase 1/Phase 2
Completed NCT00880269 - Efficacy and Safety of Panobinostat (LBH5789) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) Phase 2
Recruiting NCT05305859 - Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML Phase 2